title: Feasibility of a dose-adjusted fludarabine-melphalan conditioning prior autologous stem cell transplantation in a dialysis-dependent patient with mantle cell lymphoma.
authors.forename: Andrea
authors.initials: A
authors.lastname: Tendas
authors.forename: Luca
authors.initials: L
authors.lastname: Cupelli
authors.forename: Teresa
authors.initials: T
authors.lastname: Dentamaro
authors.forename: Laura
authors.initials: L
authors.lastname: Scaramucci
authors.forename: Roberto
authors.initials: R
authors.lastname: Palumbo
authors.forename: Pasquale
authors.initials: P
authors.lastname: Niscola
authors.forename: Marco
authors.initials: M
authors.lastname: Giovannini
authors.forename: Daniela
authors.initials: D
authors.lastname: Piccioni
authors.forename: Alessio Pio
authors.initials: AP
authors.lastname: Perrotti
authors.forename: Paolo
authors.initials: P
authors.lastname: de Fabritiis
mesh_terms: D000368:Aged; D003131:Combined Modality Therapy / Q000379:methods; D004359:Drug Therapy, Combination; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods; D006801:Humans; D020522:Lymphoma, Mantle-Cell / Q000188:drug therapy / Q000601:surgery*; D008297:Male; D008558:Melphalan / Q000008:administration & dosage*; D006435:Renal Dialysis; D019172:Transplantation Conditioning / Q000379:methods; D014740:Vidarabine / Q000008:administration & dosage / Q000031:analogs & derivatives*
chemical_list: D014740:Vidarabine; C024352:fludarabine; D008558:Melphalan